-+ 0.00%
-+ 0.00%
-+ 0.00%

Chardan Capital Maintains Buy on Palvella Therapeutics, Raises Price Target to $174

Benzinga·12/16/2025 12:25:24
语音播报
Chardan Capital analyst Geulah Livshits maintains Palvella Therapeutics (NASDAQ:PVLA) with a Buy and raises the price target from $110 to $174.